Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
In real world more comorbid nmCRPC patients with a higher ECOG-PS and more aggressive tumors are treated with apalutamide plus ADT. Nevertheless efficacy results as well as side effects are similar in real-world compared to Spartan trial showing also a rapid, durable and deep PSA response with a median MFS of 43 months.
Authors
- M. Ludwig (ORCID: https://orcid.org/0000-0001-7645-9529)
- Stefan Schultheis
- Denny Varughese
- P. Huwe
- Rainer Häußermann
- Markus Thiemer
- Sebastian Hollwegs
- Lennart Skrobek
- Anke Bartsch-Polle
- Manfred Maywurm
- Jost Weber
- M. Vink
- Axel Hegele
Institutions
- Philipps University of Marburg (DE)
- Deutscher Wetterdienst (DE)
- Kliniken Essen-Mitte (DE)
- Sozialstiftung Bamberg (DE)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1007/s00432-024-05928-7
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Philipps-Universität Marburg